BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company

BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company

PR Newswire

LUND, Sweden, Nov. 20, 2018

LUND, Sweden, Nov. 20, 2018 /PRNewswire/ --– BioInvent International AB (OMXS: BINV) announced today that it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP compliant material to support their clinical development programs.

The manufacturing agreement is expected to generate revenue of approximately USD 1.5 million, mainly in 2019.

About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program is BI-1206, currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.

BioInvent's manufacturing capabilities
The BioInvent manufacturing facility is compliant with Current Good Manufacturing Practice (cGMP) regulations and is fully based on disposable technology and can produce batches in sizes from 40 L to 1,000 L. The platform process ensures rapid and efficient process development and spans everything from cell line development to final release of drug substance for clinical trials. BioInvent offers a range of cell line development options that include a royalty free GS knocked CHO K1 cell line.

For further information, please contact:

 

 

Martin Welschof, CEO

 

Hans Herklots, LifeSci Advisors

 

+46 (0)46 286 85 50

 

+41 79 598 71 49

 

martin.welschof@bioinvent.com

 

hherklots@lifesciadvisors.com



 

BioInvent International AB (publ)


 

Co. Reg. No. Org nr: 556537-7263


 

Visiting address: Sölvegatan 41


 

Mailing address: 223 70 LUND


 

Phone: +46 (0)46 286 85 50


 

www.bioinvent.com 


The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.10 a.m. CET, on 20 November, 2018.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

http://mb.cision.com/Main/583/2677816/948772.pdf

Press release (PDF)

Voltar noticias em Inglês